| Product Unit Size | Cost | Quantity | Stock |
|---|
GSK-2578215A is a selective inhibitor of leucine-rich repeat kinase 2 (LRRK2), a potential therapeutic target for some forms of Parkinson’s disease. GSK-2578215A inhibits Ser910 and Ser935 phosphorylation in vitro. It also induces protective autophagy in SH-SY5Y cells.
| Cas No. | 1285515-21-0 |
|---|---|
| Purity | ≥98% |
| Formula | C24H18FN3O2 |
| Formula Wt. | 399.43 |
| IUPAC Name | 5-(2-fluoropyridin-4-yl)-2-phenylmethoxy-N-pyridin-3-ylbenzamide |
| Synonym | GSK2578215A; Q641JSF42X; CHEMBL2204495;GSK257821A; AK174163; 2-(benzyloxy)-5-(2-fluoropyridin-4-yl)-N-(pyridin-3-yl)benzamide; Benzamide, 5-(2-fluoro-4-pyridinyl)-2-(phenylmethoxy)-N-3-pyridinyl- |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Reith A., Bamborough P., et al. GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. Bioorg Med Chem Lett. 22(17):5625-9 (2012). PMID: 22863203.
Saez-Atienzar S., Bonet-Ponce L., et al. The LRRK2 inhibitor GSK2578215A induces protective autophagy in SH-SY5Y cells: involvement of Drp-1-mediated mitochondrial fission and mitochondrial-derived ROS signaling. Cell Death Dis. 5:e1368 (2014). PMID: 25118928.